Latest Headlines

  1. RoosterBio And Applied StemCell Partner To Advance Scalable iPSC-Based Bioprocess Solutions 7/8/2026

    Applied StemCell, Inc. ("ASC"), a biotechnology company with deep expertise and intellectual property in induced pluripotent stem cell (iPSC) technology, and RoosterBio, Inc., a leading supplier of cellular starting materials, bioprocess media, and advanced therapy manufacturing solutions, today announced a strategic partnership to develop and commercialize scalable iPSC-based bioprocess solutions.

  2. RoosterBio And Qkine Partner To Deliver A Single-Source Platform Of Cells, Media, And Growth Factors To U.S. Customers 7/7/2026

    RoosterBio, Inc., a leading supplier of cellular starting materials, bioprocess media, and advanced therapy manufacturing solutions for hMSCs, iPSCs, and exosome therapeutic developers, today announced a distribution agreement with Qkine Ltd., a Cambridge, UK–based manufacturer of high-purity, animal origin-free recombinant growth factors, cytokines, and complex bioactive proteins.

  3. Resilience Announces Relocation Of West Coast Headquarters To Ohio And Expansion Of Sterile Manufacturing Capabilities 7/1/2026
  4. Proliant Health & Biologicals Raises The Albumin Standard With AlbufreeDX: Consistent, Animal-Free Recombinant Human Albumin 6/24/2026

    Proliant Health & Biologicals announces the commercial launch of AlbufreeDX, a recombinant human albumin (rHA) designed to meet the growing demand for high-performance, animal-free ingredients across diagnostic and life science applications.

  5. Asimov Launches Chrysalis Transposase, A Wholly-Owned Genome Integration Tool For Biotherapeutics Production 6/23/2026

    Asimov announces Chrysalis transposase, a proprietary genome integration tool engineered to deliver higher titers, greater expression stability, and faster cell recovery than conventional transposases.

  6. The Ottawa Hospital's Biotherapeutics Manufacturing Centre (BMC) Makes Breakthroughs Break Through As Boreal Biomanufacturing 6/18/2026

    The Ottawa Hospital’s Biotherapeutics Manufacturing Centre (BMC), a facility that has developed more than 20 distinct cell- and virus-based products for human clinical trials in Canada, the United States, Europe and Asia, is becoming Boreal Biomanufacturing (Boreal). 

  7. Minaris Enhances GMP Cell Banking Suites At Philadelphia Facility 6/18/2026

    Minaris, a global cell and gene therapy (CGT) CDMO and multimodal biosafety testing organization, today announced the enhancement of its dedicated GMP cell banking suites at its Philadelphia facility, a centralized hub for cell banking and biosafety testing. 

  8. Recipharm Invests In U.S. Fill-Finish Infrastructure To Accelerate Biologics Development 6/17/2026

    Recipharm, a leading global contract development and manufacturing organisation (CDMO), today announced a multi-million-dollar investment in its US operations, strengthening its ability to support pharmaceutical and biotechnology companies with advanced sterile fill and finish services for biologics and advanced therapies.

  9. Annex 1 Is Not the Ceiling For Compliance; It Is The Foundation 6/11/2026

    The sterile manufacturing industry is undergoing a significant transformation as regulatory agencies shift towards a comprehensive approach to compliance. GRAM explores the implications of recent updates, such as those to Annex 1, that formed a framework for their compliance strategies through proactive contamination control, risk management, and transparency.

  10. Rezon Bio Appoints Dr. Ralf Otto As Chief Operating Officer To Support Next Phase Of Growth And Operational Expansion 6/3/2026

    Rezon Bio, a science-driven European biologics contract development and manufacturing organization (CDMO), today announced the appointment of Dr. Ralf Otto, as Chief Operating Officer (COO) effective June 1, 2026.